Glycosylation of ␤1 integrin (␤1) in the Golgi complex has been related to its function in multiple cell processes, e.g., invasiveness, matrix adhesion, and migration. Brefeldin A-inhibited guanine nucleotide-exchange proteins (BIG) 1 and BIG2 activate human ADP-ribosylation factors (ARF) 1 and ARF3 by catalyzing the replacement of ARF-bound GDP with GTP to regulate Golgi vesicular transport. We show here a requirement for BIG1 (but not BIG2) in glycosylation and function of ␤1. In HepG2 cells treated for 48 or 72 h with BIG1, but not BIG2, siRNA, both the amount and electrophoretic mobility of the initially 130-kDa ␤1 were increased. BIG1 content had risen by 48 h after removal of BIG1 siRNA, and the faster-migrating, aberrant 130-kDa ␤1 was not seen. Peptide Nglycosidase F, but not endoglycosidase H, digestion converted all ␤1 to an Ϸ85-kDa (core protein) form. By electron microscopy, Golgi membranes in BIG1-depleted cells were less sharply defined than those in mock or BIG2 siRNA-treated cells, with more vesiclelike structures at the transface. Amounts of active RhoA-GTP also were decreased in such cells and restored by overexpression of HA-BIG1. Aberrant ␤1 was present on the cell surface, but its function in cell spreading, adhesion, and migration was impaired. By immunofluorescence microscopy, BIG1 siRNA-treated cells showed less spreading and concentration of ␤1 at the cell surface. These results indicate a previously unrecognized role for BIG1 in the glycosylation of ␤1 by Golgi enzymes, which is critical for its function in developmental and other vital cell processes.
I
ntegrins are heterodimeric transmembrane glycoproteins comprising diverse ␣-and ␤-subunits. Most of the integrins involved in focal adhesion (FA) formation are members of the ␤ 1 or ␤ 3 families. The ␤1 integrin (␤1) subunit pairs with at least 12 different ␣-subunits to form transmembrane adhesion receptors for extracellular matrix (ECM) proteins, e.g., collagen, fibronectin, and laminin (1) . Integrin binding of ECM initiates intracellular signaling, including RhoA-dependent events, such as development of lamellipodia, actin stress fibers, and FAs that act in cell spreading and adhesion (2) .
The function of ␤1 depends on its accurate glycosylation catalyzed by enzymes located in morphologically and biochemically distinct cisternae of the Golgi system. Mature ␤1 is transported to the cell surface, where it mechanically links plasma membrane adhesion complexes to the actin cytoskeleton for bidirectional transmembrane as well as intracellular signaling. Numerous processes, e.g., embryogenesis, wound healing, and tumorigenesis, are regulated in this way (3, 4) ; factors that can affect ␤1 glycosylation and transport include Ki-Ras (5), transforming growth factor-␤ (6), and HEMCAM/gicerin (7) . Treatment of HeLa cells with ceramide or brefeldin A caused fragmentation of the Golgi complex and inhibition of ␤1 glycosylation (8) . Accumulated data indicate the importance of ␤1 N-glycosylation in cell adhesiveness and motility (9) .
RhoA activation functions both upstream and downstream of integrins in the formation of FAs and stress fibers (10-13).
Aggregation of integrins induced the recruitment of RhoA (14) , and activation of RhoA in turn regulated signaling downstream of integrins (15, 16) . Activity of overexpressed RhoA was greatly potentiated by coexpression of ␤1 and significantly reduced by a coexpression of a dominant-negative ␤1 mutant (17, 18) .
Brefeldin A-inhibited guanine nucleotide-exchange proteins (BIG) 1 and BIG2, like other ADP-ribosylation factor (ARF) GEF molecules, contain Ϸ200-aa Sec7 domains that catalyze replacement of ARF-bound GDP by GTP to initiate membrane vesicle formation (19, 20) . BIG1, in addition to being present in Golgi membranes, was found in nuclei of serum-starved HepG2 cells (21) , and BIG2 was seen in cytoplasmic vesicular structures that were most likely recycling endosomes (22) . Among mammalian ARFs, ARF1 and ARF3 were preferentially activated by BIG1 and BIG2 (23) . ARF1 was reported to be important for integrity of Golgi structure, and overexpression of an inactive GDP-bound ARF1 mutant caused disintegration of Golgi (24). Norman et al. (25) showed that ARF1 mediated the recruitment of paxillin to FAs and facilitated Rho-stimulated stress fiber formation in Swiss 3T3 fibroblasts, implicating it in cytoskeletal remodeling. Overexpression of ASAP1, an ARF GAP that is enriched in FAs, inhibited cell spreading and FA localization of paxillin in adhesions (26) . More recently, Liu et al. (27) presented evidence that the ARF1 activation cycle may be critical for regulation of adhesion complex dynamics in response to integrin engagement and activation.
Here, we show a requirement for BIG1, but not BIG2, in maturation of ␤1. Suppressing BIG1 expression with siRNA duplexes impaired N-linked glycosylation of ␤1 and significantly inhibited cell spreading, adhesion, and migration. The activity of RhoA, an important regulator of FAs, was decreased by BIG1 siRNA and restored by overexpression of HA-BIG1. By electron microscopy, the integrity of Golgi membranes appeared compromised in BIG1 siRNA-treated cells. These results identify a previously unrecognized role for BIG1 in cytoskeletal dynamics through integrin ␤1-mediated signaling.
Results

BIG1
, Not BIG2, siRNA Impaired Maturation of ␤1 in HepG2 Cells. Cells incubated with vehicle alone or with nontarget (NT) siRNA contained two forms of immunoreactive ␤1 separated by SDS/ PAGE, the 110-kDa ␤1 precursors in a broad band with a less Author contributions: X.S., J.M., and M.V. designed research; X.S. and M.-S.H. performed research; X.S., M.-S.H., J.M., and M.V. analyzed data; and X.S., M.-S.H., and M.V. wrote the paper.
intense, Ϸ130-kDa band of mature ␤1 above (Fig. 1A, lane 1) . There was little difference in the appearance of ␤1 in cells incubated for 24 h with BIG1 or BIG2 siRNA, although amounts of the respective target proteins clearly were diminished and still were lower after 48 and 72 h (Fig. 1 A) . By 48 h of BIG1, but not BIG2, siRNA treatment, both intensity and migration were increased in the Ϸ130-kDa glycosylated ␤1 band. This finding was more evident at 72 h, when essentially no remaining mature BIG1 was seen ( Fig. 1 A, lane 3) , and amounts of the aberrant Ϸ130-kDa ␤1 were significantly greater than those of ''normal'' ␤1 in control cells (Fig. 1B) . The amount of Ϸ110-kDa ␤1 did not differ significantly in any condition. We concluded that BIG1 siRNA treatment interfered with ␤1 maturation. The fastermigrating immature 130-kDa ␤1 was still evident 24 h after removal of BIG1 siRNA but not at 48 h, when BIG1 content had risen to Ϸ46% of that in untreated cells (Fig. 1C) .
BIG1 siRNA Treatment Impaired ␤1 N-Linked Glycosylation. To ascertain whether the aberrant ␤1 seen after BIG1 siRNA treatment reflected impaired N-glycosylation, lysates of HepG2 cells were digested with endoglycosidase H (Endo H) or peptide N-glycosidase F (PNGase F) before Western blot analyses. Endo H cleaves N-linked glycoproteins to remove the chitobiose core of mannose and some hybrid oligosaccharides. PNGase F is an amidase that removes all saccharide moieties. Endo H digestion completely converted the 110-kDa ␤1 to a band of Ϸ85 kDa (the size of the core protein), whereas 130-kDa ␤1, which is glycosylated by medial-and trans-Golgi enzymes, was Endo Hresistant; only the 85-kDa band of ␤1 was seen after PNGase F digestion ( Fig. 2A) . Addition of N-acetylglucosamine to glycoproteins, which occurs in the medial-Golgi, results in Endo H resistance. To assess whether galactosylation (in trans-Golgi cisternae) or sialylation [in trans-Golgi network (TGN)] of ␤1 was affected by BIG1 siRNA, we used neuraminidase to remove all nonreducing, terminal branched and unbranched sialic acids. The enzyme did not alter mobility of the aberrant ␤1 from cells treated with BIG1 siRNA (Fig. 2B) , consistent with its failure to have been modified in the TGN.
To determine whether BIG1 depletion affected only ␤1 glycosylation, we looked at two other cell-surface glycoproteins. Like ␤1, intercellular adhesion molecule 1 (ICAM-1), but not E-cadherin, from cells treated with BIG1 siRNA migrated slightly faster than that from control cells. It appeared also to be somewhat increased in amount; both differences were more apparent after neuraminidase treatment (Fig. 2B) .
BIG1, but Not BIG2, siRNA Treatment Altered Golgi Structure. The aberrant glycosylation of ␤1 (and ICAM-1) may reflect an effect of BIG1 siRNA treatment on Golgi function. By using electron microscopy, the Golgi membranes in BIG1 siRNA-treated cells appeared to be much less compact and sharply defined or arranged than those in mock or BIG2 siRNA-treated cells (e.g., in Fig. 3 ). In addition, more vesicle-like structures were seen at the trans-Golgi face (T) in HepG2 cells treated with BIG1 siRNA.
Immature Integrin ␤1 on the Cell Surface. Presence of aberrant 130-kDa ␤1 on the surface of HepG2 cells treated with BIG1 siRNA was confirmed by biotinylation of proteins exposed to the external medium (Fig. 4A) . No biotinylated immature 110-kDa ␤1 was detected on the surface of any cells. The 130-kDa mature ␤1 (and its aberrant form in cells treated with BIG1 siRNA) were the only immunoreactive ␤1 bands detected among biotinylated cell-surface proteins. The electrophoretic mobility of ICAM-1, like that of ␤1, was increased in cells treated with BIG1 siRNA, whereas E-cadherin mobility was unchanged. As quantified by densitometry, amounts of aberrant forms of both ␤1 and ICAM-1 were greater at the cell surface than those in control cells [␤1, 1.38 Ϯ 0.026; ICAM-1, 1.18 Ϯ 0.008 vs. mock ( Fig. 4B) ].
The aberrant cell-surface ␤1 was unaffected by Endo H, but migration of immunoreactive ␤1 was similar to that of controls after PNGase F digestion, as seen with ␤1 from cells in Fig. 2  (Fig. 4C) . Thus, aberrant ␤1 was transported to the cell surface, probably as a heterodimer with an ␣-integrin, but its functional capacity was unclear.
Effect of BIG1 siRNA on HeLa Cells Spreading on Type I Collagen.
Integrins act to regulate both FA assemblies and actin filaments. Cell-surface ␤1 as a heterodimer with an ␣-subunit is critical in FA structure and function. For microscopic visualization of ␤1 immunofluorescence, we used HeLa cells (Fig. 5) . Spreading of BIG1 siRNA-treated cells on collagen I was much slower than that of other cells, and the distribution of intracellular ␤1 also differed. Concentrations of ␤1 at the surface of cells in mock, NT, and BIG2 siRNA-treated groups, presumably in FAs after 40 min of incubation, were increasingly visible, along with intercellular connections. Cells treated with BIG1 siRNA, however, spread very little, and neither ␤1 immunoreactivity in FAs nor connections between cells were seen. Although the aberrant ␤1 in BIG1 siRNA-treated cells was present at the cell surface, its structural function(s) appeared clearly altered.
Aberrant Integrin ␤1 Affects Cell Adhesion and Migration. To evaluate function of the aberrant ␤1 in HepG2 cells treated with BIG1 siRNA, we quantified cell attachment to collagen I or ␤1 antibodies and migration without or with a chemotactic stimulus. Cells treated with BIG1 siRNA attached to the type I collagencoated surface significantly more slowly than those in mock, NT, or BIG2 siRNA-treated groups (Fig. 6A) . Binding of cells treated with BIG1 siRNA to the anti-␤1 monoclonal antibody-coated plate after 60 min was only 64.0% Ϯ 2.13% (n ϭ 3) that of cells treated with vehicle alone (Fig. 6B) , whereas BIG2 siRNAtreated cells were unaffected.
Either BIG1 or BIG2 siRNA treatment significantly decreased migration in the presence of FBS ( Fig. 6C ; *, P Ͻ 0.05, BIG1 siRNA 200 Ϯ 18.7; BIG2 siRNA 207 Ϯ 11.7) but not migration in the absence of serum.
Effects of BIG1 siRNA and HA-BIG1 Overexpression on Active RhoA-GTP in HepG2 Cells. Formation of stress fibers and FAs requires activated RhoA-GTP. The relationship between changes in ␤1 (amount or glycosylation) and RhoA activation was evaluated in cells that had been incubated without serum for 18 h. As shown in Fig. 7A , amounts of total RhoA were similar in all cells. RhoA-GTP contents of those incubated with vehicle or with NT or BIG2 siRNA also were similar but were undetectable in cells treated with BIG1 siRNA. Incubation for 20 min with 10% FBS markedly increased RhoA-GTP in all cells, although the amount in those treated with BIG1 siRNA remained lower than the others ( Fig. 7A ; 0.74 Ϯ 0.015 vs. mock). When cells that had been depleted of BIG1 (Fig. 7B, lanes 2-4) were overexpressing Fig. 1 A (lanes 1-4) . Samples of total lysate proteins (10 g) or biotinylated cell-surface proteins from 10 g of total lysate were separated in 4 -12% NuPAGE Bis-Tris Gels, followed by reaction with indicated antibodies. HA-tagged BIG1 (Fig. 7B, lane 4) , RhoA-GTP content approximated that of cells treated with vehicle alone (Fig. 7B, lane 1) , whereas levels in those transfected with empty vector, or in BIG1-depleted cells after serum starvation or FBS restoration, did not differ.
Discussion
As reported here, treatment of HepG2 cells with BIG1, but not BIG2, siRNA altered ␤1 glycosylation. With partial restoration of BIG1 after siRNA removal, ␤1 maturation was restored, consistent with a role for BIG1 in that process. The mature 130-kDa ␤1 in control mock or NT siRNA-treated cells, as well as its faster-migrating form in BIG1 siRNA-treated cells, were resistant to Endo H digestion, and all yielded products of the same size after deglycosylation with PNGase F, leading to the inference that impairment of ␤1 glycosylation caused by BIG1 siRNA was not at the cis-Golgi, but probably later, after medialGolgi modification of the protein.
The stability and functions of many plasma membrane and secreted proteins depend on accurate glycosylation catalyzed by enzymes located in specific Golgi regions. Different enzymes are present in morphologically and biochemically distinct cisternae (cis-, medial-, and trans-) of the Golgi system, which are arranged in a manner that facilitates (temporally and spatially) the correct sequence of posttranslational modifications. N-linked glycosylation begins in the endoplasmic reticulum, where mannose moieties, which are removable by Endo H-catalyzed cleavage, are added. These glycoproteins move through the cis-to medialGolgi, where N-acetylglucosamine is added and two mannose molecules are removed, resulting in acquisition of Endo H resistance. In the trans-Golgi cisternae, galactose molecules are added and modification is completed in the TGN by attachment of sialic acid moieties.
Variant ␤1 glycosylation has been related to its function in multiple processes, e.g., cytotrophoblast invasiveness (28), cellmatrix adhesion and migration (29) , or melanoma progression (30) , as well as to the identity of integrin-interacting extracellular molecules (31) . The most commonly reported differences in glycosylation of ␤1 resulted from variations in the degree of sialylation or of ␤1-6 branching in N-linked oligosaccharides (30, (32) (33) (34) . After neuraminidase cleavage of all nonreducing terminal (branched and unbranched) sialic acids, the aberrant Ϸ130-kDa ␤1 (as well as ICAM-1) from cells treated with BIG1 siRNA still migrated more rapidly than the proteins from control cells, consistent with defective ␤1-6 branching of N-linked oligosaccharides. This modification is catalyzed by ␤1-6 Nacetylglucosaminyltransferase V, a trans-Golgi enzyme, which may be related to the apparent colocalization of BIG1 and a TGN marker, TGN38, seen with confocal immunofluorescence microscopy (35) .
Unlike other integrin subunits, intracellular ␤1 exists regularly as a partially glycosylated, 110-kDa precursor in the endoplasmic reticulum and as a completely glycosylated form (130 kDa) at the cell surface (30, (36) (37) . BIG1 siRNA did not alter the amount of 110-kDa ␤1 seen on immunoblotting, but that of the Golgimodified 130-kDa ␤1 was clearly increased. A lack of BIG1 (or BIG2) would, presumably, halt protein trafficking at sites where it is required to activate a class I ARF and thereby initiate vesicle generation for the next stage of transport to the cell surface. Different glycoproteins are processed at different Golgi sites, and although glycosylation of ICAM-1 also was altered after BIG1 siRNA treatment, that of E-cadherin apparently was not affected. Mutation of yeast Gea1p and Gea2p, members of Sec7/BIG family of ARF activators, resulted in defective protein glycosylation and slowed secretion (38) . Impaired glycosylation was not caused by decreased glycosyl transferase activity in those cells but by alteration of Golgi structures containing enzymes Fig. 1 A  (lanes 1-4) , then for 18 h in DMEM without serum (SS), and 20 min in DMEM containing 10% FBS. Samples (30 g) of total cell protein or of RhoA-GTP isolated from another sample by binding to Rhotekin agarose were separated in NuPAGE Bis-Tris Gels and reacted with antibodies against BIG1, BIG2, or RhoA. Amounts of RhoA-GTP in three experiments quantified by densitometry and expressed relative to that of the protein in mock cells that catalyze both early and late modifications (38) (8) . Consistent with those reports, the morphology of HepG2 cell Golgi cisternae appeared altered after BIG1 siRNA treatment in our experiments. Membranes were less sharply defined and clearly separated from each other, with more vesicle-like structures seen at the transface of the Golgi.
Despite defective N-glycosylation, presumably because of impaired trafficking at the TGN caused by BIG1 siRNA treatment, the aberrant Ϸ130-kDa ␤1 (unlike the 110-kDa form) was transported to the cell surface. Thus, the question of its functionality became relevant. Altered behavior of abnormally glycosylated ␤1, for example, in cell spreading, adhesion to ECM, motility/ invasiveness, and anchorage-independent growth of tumor cells, has been reported (29, 39, 40) . As expected, BIG1 siRNA-treated HeLa cells showed significantly delayed spreading on type I collagencoated slides after 90 min, along with altered distribution of intracellular ␤1. BIG1, but not BIG2, depletion also interfered with cell migration and ␤1-mediated cell-matrix adhesion. Guo et al. (29) found that aberrant N-glycosylation of ␤1 caused by overexpression of N-acetylglucosaminyltransferase V reduced cell content of integrin ␣5␤1 along with inhibition of cell spreading and adhesion on fibronectin, which were associated with enhanced cell migration. In our experiments, the aberrant N-glycosylation of ␤1 in cells treated with BIG1 siRNA was associated with impaired chemotaxis, perhaps secondary to defective cell-matrix adhesion. Inhibition of chemotaxis after BIG2 siRNA treatment perhaps is related to the demonstrated effect of BIG2 depletion on transferrin recycling (22) , which may involve Exo70 and the exocyst complex (41) . In addition, cell migration requires the regulated termination and regeneration of ␤1 interactions with ECM and the cytoskeleton, which depend on activation of ARF6 by GEP100/BRAG2 that controls ␤1 endocytosis and actin remodeling (42, 43) .
Numerous studies have demonstrated that integrin-mediated spreading and adhesion to the ECM regulates the activity of the Rho family of small GTP-binding proteins (10) (11) (12) (13) (14) (15) (16) (17) (18) . Adhesion to fibronectin or other integrin engagement was sufficient to enhance RhoA-dependent stress fibers (15) . Adhesion to fibronectin altered RhoA activity in three phases: initial inactivation was followed by activation between 60 and 90 min and then a gradual decrease by 2-3 h (44). Inactivation of RhoA by p190RhoGAP in response to integrin-mediated adhesion contributes to efficient cell spreading and migration by enhancing both membrane protrusion and cell polarity (13) , consistent with reports of reciprocal influences of ␤1 and RhoA activation. We found that the abnormally glycosylated ␤1 resulting from BIG1 siRNA treatment was delivered to the cell surface but did not function normally in FAs. Cell content of activated RhoA-GTP was low, and both cell adhesion and chemotaxis were impaired. All observations reported here point to BIG1 action in the late Golgi region (trans-Golgi and TGN) that is important for the accurate N-linked glycosylation of ␤1 but apparently is not required for ␤1 translocation from Golgi to the plasma membrane. It remains to be determined whether the demonstrated deficits in RhoA activation that accompanied impairment of cell spreading, cell-matrix adhesion, and migration of cells treated with BIG1 siRNA resulted entirely from the aberrant ␤1 or reflected, at least in part, the requirement for the activation of another ARF that is itself involved in RhoA activation.
Materials and Methods
Antibodies and Reagents. Affinity purification of rabbit anti-BIG1 and anti-BIG2 antibodies has been described (22) . Mouse monoclonal antibody against ␤1(clone JB1A) was purchased from Chemicon (Temecula, CA); mouse monoclonal anti-E-cadherin antibody (clone 36) was obtained from BD Biosciences (San Jose, CA); rabbit anti-RhoA and ICAM-1 polyclonal antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); rabbit anti-HA polyclonal antibodies and ␣-2(3, 6, 8, 9) neuraminidase were obtained from Sigma (St. Louis, MO); kits for active Rho, ␤1-mediated cell adhesion, and QCM chemotaxis 96-well cell migration assays were from Upstate (Charlottesville, VA); a kit for cell-surface protein isolation (Pinpoint) was obtained from Pierce (Rockford, IL); EDTA-free protease inhibitor was from Roche (Basel, Switzerland); and Endo H and PNGase F (glycerol-free) were purchased from New England BioLabs (Ipswich, MA).
siRNA and BIG1 Overexpression. All siRNAs and related reagents were purchased from Dharmacon Research (Lafayette, CO) and used as described (22) . Plasmid pCMV-HA encoding full-length HA-BIG1 (45) was kindly provided by Heather Jones (PulmonaryCritical Care Medicine Branch, National Heart, Lung, and Blood Institute), who prepared it. HepG2 cells in 100-mm plates were transfected by using GeneJuice reagent (Novagen, San Diego, CA) according to the manufacturer's instructions. Enzymatic Deglycosylation. After experimental treatment as described, HepG2 cells were washed with ice-cold PBS, scraped, and homogenized in MLB lysis buffer [25 mM Hepes (pH 7.5), 150 mM NaCl, 1% igepal CA-630, 10 mM MgCl 2 , 1 mM EDTA, 25 mM NaF, 1 mM Na 3 VO 4 , and EDTA-free protease inhibitor]. Samples of homogenate proteins (80 g) were boiled for 10 min in denaturing buffer (supplied by company) and incubated for 3 h at 37°C with Endo H (2 l), PNGase F (2 l), or ␣-2(3, 6, 8, 9) neuraminidase before separation of samples (20 g) in 4-12% NuPAGE Bis-Tris Gel (Invitrogen, Carlsbad, CA) and immunoblotting with antibodies against ␤1, ICAM-1, or E-cadherin.
Cell-Surface Protein Isolation. Biotinylated cell-surface proteins were isolated according to the manufacturer's protocol. Briefly, after experimental treatment, cells in a 100-mm plate were rinsed three times with ice-cold PBS and incubated (30 min at 4°C) in 10 ml of PBS containing 0.24 mg/ml EZ-link Sulfo-NHS-SS-Biotin (Pierce) before reaction was quenched. Cells collected by scraping gently were washed twice with TBS and homogenized in 400 l of lysis buffer (Pierce). Samples of homogenates (300 g of protein in 300 l) were mixed (end-over-end, 1 h at room temperature) with 300 l of immobilized NeutrAvidin Gel (Pierce), which then was washed, and bound biotinylated proteins were eluted in 300 l of LDS sample buffer containing 50 mM DTT. Samples (10 l) were separated by electrophoresis in 4-12% NuPAGE Bis-Tris Gel for immunoblotting.
Activated Rho-GTP Assay. After siRNA treatment as described, cells were incubated (18 h at 37°C) in DMEM without serum, followed by 20 min in DMEM containing 10% FBS, before homogenization in 600 l of MLB lysis buffer. Rho-GTP was separated from samples (1 mg of protein in 500 l) of homogenates and quantified after immunoblotting by using the assay rhotekin kit from Upstate according to the manufacturer's instructions.
Assay of Cell Adhesion and Cell Migration. HepG2 cell adhesion to collagen I was assayed as described in ref. 42 . To evaluate adhesion resulting from ␤1 antibody reaction, HepG2 cells were harvested and dispersed in DMEM containing 10% FBS; 100-l samples (5 ϫ 10 4 cells) were added to plates coated with monoclonal antibody against ␤1 or with control IgG. After incubation (1 h at 37°C) in an atmosphere of 5% CO 2 /95% air, adherent cells were quantified according to the manufacturer's instructions.
To evaluate cell migration, COS7 cells (5 ϫ 10 4 in 100 l), after the indicated treatment, were added to upper chambers of migration assemblies with lower chambers containing 100 l of DMEM without or with 10% FBS. After incubation (4 h at 37°C) in an atmosphere of 5% CO 2 /95% air, cells accumulated in the filter separating the chambers were quantified according to the manufacturer's instructions.
